摘要
目的:探讨非布司他与别嘌醇对慢性肾脏病(CKD)伴高尿酸血症(HUA)患者的影响。方法:选取2019年9月—2023年2月贵州医科大学附属乌当医院收治的100例CKD伴HUA患者。根据随机数表法将其分为对照组和观察组,各50例。对照组给予别嘌醇片,观察组给予非布司他片。比较两组临床疗效,治疗前后炎症因子、肾功能及不良反应。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)及髓过氧化物酶(MPO)水平均降低,观察组TNF-α、IL-6、MPO水平均低于对照组,差异有统计学意义(P<0.05)。治疗后,两组血尿素氮(BUN)、血肌酐(Scr)、血尿酸(SUA)及尿微量白蛋白均降低,肾小球滤过率估计值(eGFR)升高,观察组BUN、Scr、SUA及尿微量白蛋白均低于对照组,eGFR高于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论:相较于别嘌醇,采用非布司他治疗CKD伴HUA患者效果更加显著,可更好地降低血清炎症因子水平,改善肾功能,且不良反应发生率较低。
Objective:To explore the effect of Febuxostat and Allopurinol on chronic kidney disease(CKD)with hyperuricemia(HUA).Method:A total of 100 patients with CKD and HUA admitted to Wudang Hospital Affiliated to Guizhou Medical University from September 2019 to February 2023 were selected.They were divided into control group and observation group according to random number table method,with 50 cases in each group.The control group was given Allopurinol Tablets,and the observation group was given Febuxostat Tablets.The clinical efficacy,inflammatory factors,renal function before and after treatment and adverse reactions were compared between the two groups.Result:The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)and myeloperoxidase(MPO)in both groups were reduced,and the levels of TNF-α,IL-6 and MPO in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,blood urea nitrogen(BUN),blood creatinine(Scr),blood uric acid(SUA)and urinary microalbumin were decreased in both groups,and the estimated glomerular filtration rate(eGFR)was increased,BUN,Scr,SUA and urinary microalbumin in observation group were lower than those in control group,and eGFR was higher than that in control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in observation group was lower than that in control group,and the difference was statistically significant(P<0.05).Conclusion:Compared with Allopurinol,Febuxostat is more effective in the treatment of CKD patients with HUA,which can better reduce the level of serum inflammatory factors and improve renal function,and the incidence of adverse reactions is lower.
作者
毛静静
MAO Jingjing(Wudang Hospital Affiliated to Guizhou Medical University,Guiyang 550018,China)
出处
《中外医学研究》
2024年第12期67-70,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
慢性肾脏病伴高尿酸血症
非布司他
别嘌醇
临床疗效
炎症因子
肾功能
不良反应
Chronic kidney disease with hyperuricemia
Febuxostat
Allopurinol
Clinical efficacy
Inflammatory factors
Renal function
Adverse reactions
